SCHEMBL4670609

SCHEMBL4670609

O=C(Cc1c[nH]c(S(=O)(=O)c2ccc(Cl)cc2)c1)C(=O)c1nn[nH]n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR3 P49682 8/20 0.37
TBXA2R P21731 1/20 0.36
NAMPT P43490 1/20 0.33
ALDH1A1 P00352 4/20 0.32
CYP3A4 P08684 1/20 0.32
MAPK1 P28482 1/20 0.32
CYP2C19 P33261 1/20 0.32
L3MBTL1 Q9Y468 2/20 0.32
NPC1 O15118 2/20 0.32
HTT P42858 2/20 0.32
NPSR1 Q6W5P4 2/20 0.32
LMNA P02545 1/20 0.32
AGTR1 P30556 1/20 0.32
RAB9A P51151 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
GPR55 Q9Y2T6 1/20 0.32
EGFR P00533 1/20 0.32
ERBB2 P04626 1/20 0.32
AKR1B1 P15121 1/20 0.32
KDM1A O60341 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4673217 0.90 CES1 (0.38) NAMPTCYP2C19
SCHEMBL4673275 0.89 RORC (0.35) CXCR3NAMPTCYP2C19EGFRERBB2
SCHEMBL4671924 0.83 NAMPT (0.35) TBXA2RNAMPTALDH1A1CYP3A4MAPK1
SCHEMBL4679761 0.81 ALDH1A1 (0.36) CXCR3TBXA2RNAMPTALDH1A1CYP3A4
SCHEMBL4672286 0.80 CXCR3 (0.36) CXCR3TBXA2RNAMPTALDH1A1CYP3A4
SCHEMBL4675369 0.80 CXCR3 (0.36) CXCR3TBXA2RNAMPTALDH1A1CYP3A4
SCHEMBL4675060 0.80 CXCR3 (0.36) CXCR3TBXA2RALDH1A1CYP3A4MAPK1
SCHEMBL4671388 0.80 CXCR3 (0.36) CXCR3TBXA2RALDH1A1CYP3A4MAPK1
SCHEMBL4675557 0.77 CXCR3 (0.35) CXCR3TBXA2RALDH1A1CYP3A4MAPK1
SCHEMBL4672021 0.77 CXCR3 (0.35) CXCR3TBXA2RALDH1A1CYP3A4MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 CXCR3 1130/4885TBXA2R 2734/4885NAMPT 2333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.